Drug-Drug-Dietary interactions in pharmacotherapy of GIT medication: A review

Successful drug therapy depends on the interaction between drug-drug and drug-diet. Drug interactions are a vital reason for causing adverse drug reactions and modify one drug effect by another drug and these kinds of interactions can increase or decrease the effectiveness of the drug. Polypharmacy could be a major risk for Drug-Drug and Drug-food interactions. Food Consumption can alter the effect of drugs by interfering either with their pharmacokinetics or pharmacodynamics processes. Anti-ulcer drugs are used to treat different types of ulcer and that may interact with another drug showing undesirable effects. GIT medications interfere with another type of medication either with at the pharmacokinetic and pharmacodynamic level. The main objective of this article is to review data regarding common Drug-drug & Drug-food interactions related to GIT medications. Data was collected from Google Scholar, PubMed, and Scopus databases, and they were reviewed for publication on drug-drug & drug-food interactions related to GIT medications. This data is very helpful for pharmacists while reviewing and analyzing prescribed medication, especially in geriatrics prescriptions.

Effect of standardized ileal digestible lysine on growth and subsequent performance of weanling pigs1

A total of 320 weanling pigs (all barrows, initially 5.71 kg BW; Line 1050, PIC Hendersonville, TN) were used to determine whether the Lys level fed during one phase of the nursery influences the response to Lys during subsequent phases. Our hypothesis was that feeding decreasing dietary Lys concentration in early phases, but feeding adequate concentrations in later phases might result in similar pig growth as those fed a more conventional approach with step-wise decreases in dietary Lys as pigs become heavier. Eight dietary regimens were used in a split-plot design. There were three dietary phases, and within phase, a high or low standardized ileal digestible (SID) Lys diet was fed. Pigs were fed either 1.35% or 1.55% SID Lys during phase 1 (days 0 to 7), 1.15% or 1.35% SID Lys in phase 2 (days 7 to 21), and 1.05 or 1.25% SID Lys during phase 3 (days 21 to 35). The low dietary Lys concentrations were achieved by reducing both crystalline Lys and intact protein sources from the high Lys diets. From days 0 to 7, feeding high SID Lys improved (P < 0.01) G:F, but no evidence for differences in ADG or ADFI were observed. Similarly, from days 7 to 21, there were no evidence for differences in ADG or ADFI among pigs fed the two Lys levels, but those fed high SID Lys had improved (P < 0.03) G:F. From days 21 to 35, pigs fed the high Lys diet had increased (P < 0.01) ADG and G:F compared with those fed low SID Lys, but there were no effects on ADFI. For the overall trial (days 0 to 35), there were no dietary interactions among phases, indicating that the Lys level fed in each phase did not influence the response to Lys in subsequent phases. Thus, pigs fed the high Lys level during phase 3, regardless of previous Lys levels in phases 1 and 2, had greater (P < 0.05) overall ADG and G:F compared with other treatment groups. In conclusion, relatively low dietary Lys concentrations can be fed in the early nursery phases (approximately 6 to 12 kg) without any negative impact on overall growth performance provided that adequate Lys levels are fed thereafter (12 to 20 kg).